Details About Generic Salt ::  Edetate1

Main Medicine Class:: Cardiovascular   

(EH-duh-tate die-SO-dee-uhm)
Chealamide, Disotate, Endrate
Class: Cardiovascular

 

Drugs Class ::

 Action Forms chelates with polyvalent metals, especially calcium, thus increasing their urinary excretion.

Indications for Drugs ::

 Indications Emergency treatment of hypercalcemia; control of ventricular arrhythmias associated with digitalis toxicity.

Drug Dose ::

 Route/Dosage

ADULTS: IV 50 mg/kg/day (maximum 3 g/day). Usually administered in 5 consecutive daily doses followed by 2 days without medication, with repeated courses prn, for total of 15 doses. CHILDREN: IV 40 mg/kg/day (maximum 70 mg/kg/day) or 15–50 mg/kg/day (maximum 3 g/day) with 5 days between courses.

Contraindication ::

 Contraindications Anuria.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Special risk patients: Use drug cautiously in patients with limited cardiac reserve or incipient congestive failure. Diabetic patients: Blood sugar and insulin requirements may be lower in insulin-dependent diabetic patients. IV infusion: Rapid IV infusion or high serum concentrations can cause a precipitous and potentially fatal drop in serum calcium. Do not exceed maximum dose or rate.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Transient drop in BP; adverse effects on myocardial contractility; thrombophlebitis. CNS: Transient circumoral paresthesia; numbness; headache. DERM: Exfoliative dermatitis; toxic skin and mucous membrane reactions. GI: Nausea; vomiting; diarrhea. GU: Nephrotoxicity; damage to reticuloendothelial system. HEMA: Thrombophlebitis; anemia. META: Electrolyte imbalances including hypocalcemia, hypokalemia, and hypomagnesemia; hyperuricemia. OTHER: Febrile reactions.

Drug Mode of Action ::  

 Action Forms chelates with polyvalent metals, especially calcium, thus increasing their urinary excretion.

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note previous history of renal disease or CHF.
  • Because of potential for electrolyte disturbances, obtain appropriate laboratory determinations (electrolytes, calcium, renal function test).
  • Adequately hydrate patient before administration.
  • Assess patency of IV site frequently during therapy.
  • Assist patient with ambulation.
  • After infusion, have patient remain supine for short period because of possible orthostatic hypotension.
  • Assess for allergic reaction: rash, urticaria. Withhold drug and notify physician if these signs occur.
  • Monitor vital signs and I&O.
  • Monitor rate of infusion closely.
  • If signs or symptoms of hypocalcemia occur (circumoral numbness/tingling, positive Chvostek’s or Trousseau’s signs, tetany), notify physician.
  • If signs or symptoms of cardiac dysfunction occur (tachycardia, arrhythmias, hypotension), notify physician.
OVERDOSAGE: SIGNS & SYMPTOMS
  Drop in serum calcium

Drug Storage/Management ::

 Administration/Storage

  • Do not confuse edetate disodium with edetate calcium disodium.
  • ADULTS: Dissolve 50 mg/kg dose in 500 ml of D5W or 0.9% Sodium Chloride for Injection. Infuse over ³ 3 hr.
  • Children: Dissolve drug in sufficient volume of D5W or 0.9% Sodium Chloride for Injection to bring final concentration to £ 3%. Infuse over ³ 3 hr.
  • Store at room temperature.

Drug Notes ::

 Patient/Family Education

  • Advise patient to remain recumbent for 30 min after infusion because of possibility of orthostatic hypotension.
  • Inform patient that breath may be odorous.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.